First Manhattan’s Aerie Pharmaceuticals AERI Stock Holding History

First Manhattan’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-454,216	Closed	-$6.14M	–	1588
2020 Q4	$6.14M	Sell	454,216 -24,150	-5%	-$292K	0.03%	209
2020 Q3	$5.63M	Sell	478,366 -124,500	-21%	-$1.52M	0.03%	204
2020 Q2	$8.9M	Sell	602,866 -527,929	-47%	-$7.81M	0.05%	157
2020 Q1	$15.3M	Buy	1,130,795 +502,700	+80%	+$9.54M	0.1%	107
2019 Q4	$15.2M	Buy	628,095 +53,550	+9%	+$1.11M	0.08%	127
2019 Q3	$11M	Buy	+574,545	New	+$13.2M	0.06%	158

Other funds holding AERI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

First Manhattan's AERI Position: Q1 2021 in Review

First Manhattan sold out of Aerie Pharmaceuticals (AERI) in Q1 2021, closing a stake of 454,216 shares — an estimated $6.14M sold.

First Manhattan first reported a position in AERI in Q3 2019 and held it in 6 quarters. The position peaked at $15.3M in Q1 2020. 158 funds tracked by Wall St. Rank hold AERI as of Q1 2021.

First Manhattan reported no remaining Aerie Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
First Manhattan sold 454,216 Aerie Pharmaceuticals shares in Q1 2021, an estimated $6.14M.
First Manhattan first reported a position in Aerie Pharmaceuticals in Q3 2019 and held it in 6 quarters.
First Manhattan's Aerie Pharmaceuticals position peaked at $15.3M in Q1 2020.
158 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2021.

Based on First Manhattan's 13F filing for Q1 2021, filed 14 May 2021.